Modern clinical trials of new drug developments take place in study centers that may be located in multiple countries. Given the strict regulatory environment for clinical studies, specific terminology has developed over time that must be reflected in appropriate and useful translations.

German-speaking correspondence from regulatory bodies, pharmacovigilance units, and ethics committees can contain acronyms and references to German, Austrian, or Swiss legislation. Considering the major investment value of clinical trials, accurate translations of such highly relevant correspondence take out the guesswork and provide assurance that every instruction and request is understood properly without wasting time and resources.